These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

581 related items for PubMed ID: 26579834

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
    Schernthaner G, Lavalle-González FJ, Davidson JA, Jodon H, Vijapurkar U, Qiu R, Canovatchel W.
    Postgrad Med; 2016 Nov; 128(8):725-730. PubMed ID: 27391951
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
    Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P.
    Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
    [Abstract] [Full Text] [Related]

  • 5. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
    Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, Millington D, Vercruysse F, Canovatchel W, Meininger G.
    Diabetes Care; 2015 Mar; 38(3):355-64. PubMed ID: 25205142
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.
    John M, Cerdas S, Violante R, Deerochanawong C, Hassanein M, Slee A, Canovatchel W, Hamilton G.
    Int J Clin Pract; 2016 Sep; 70(9):775-85. PubMed ID: 27600862
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.
    Davies MJ, Merton K, Vijapurkar U, Yee J, Qiu R.
    Cardiovasc Diabetol; 2017 Mar 21; 16(1):40. PubMed ID: 28327140
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
    Rodbard HW, Seufert J, Aggarwal N, Cao A, Fung A, Pfeifer M, Alba M.
    Diabetes Obes Metab; 2016 Aug 21; 18(8):812-9. PubMed ID: 27160639
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
    Davidson JA, Sloan L.
    Adv Ther; 2017 Jan 21; 34(1):41-59. PubMed ID: 27854055
    [Abstract] [Full Text] [Related]

  • 13. A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
    Patel CA, Bailey RA, Vijapurkar U, Meininger G, Blonde L.
    BMC Health Serv Res; 2016 Aug 05; 16(a):356. PubMed ID: 27495291
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
    Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J.
    Cardiovasc Diabetol; 2017 Feb 27; 16(1):29. PubMed ID: 28241822
    [Abstract] [Full Text] [Related]

  • 17. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K, Kline I, Fung A, Mayer C, Meininger G.
    Postgrad Med; 2014 May 27; 126(3):16-34. PubMed ID: 24918789
    [Abstract] [Full Text] [Related]

  • 18. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF, Xie J, Sherman SE, Garceau C.
    Clin Ther; 2017 Nov 27; 39(11):2230-2242.e2. PubMed ID: 29103664
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus.
    Gavin JR, Davies MJ, Davies M, Vijapurkar U, Alba M, Meininger G.
    Curr Med Res Opin; 2015 Nov 27; 31(9):1693-702. PubMed ID: 26121561
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.